Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels

Hiroshi Kishikawa, Kayoko Hukuhara, Asako Ito, Kyoko Arahata, Sakiko Takarabe, Shogo Kaida, Jun Miyauchi, Soichiro Miura, Takanori Kanai, Jiro Nishida

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Backgrounds/Aims: In the ABC method, which is a method for risk stratification of gastric cancer using serum anti-Helicobacter pylori antibody and pepsinogen (PG) test, subjects with normal PG and seronegative for H. pylori are named as “Group A” and are regarded as having a low risk of gastric cancer. These “Group A” subjects include unintentionally eradicated cases at relatively high risk, and this study aimed to identify these subjects. Methods: Of the 109 subjects, 76 were classified as uninfected Group A subjects with negative histologic H. pylori infection and no histologic and endoscopic atrophy, and 33 subjects were classified serologically as Group A after successful eradication, which are serologically equal to the unintendedly eradicated cases in Group A. The usefulness of measuring PG levels to detect post-eradication cases was validated by using a receiver operating characteristic (ROC) curve analysis. Results: The area under the ROC curve for PGI level was 0.736 ± 0.06 (p < 0.01; cutoff value, 37.0 ng/mL; sensitivity, 77.6%; specificity, 72.7%), and that for the PGI/II ratio was 0.660 ± 0.06 (p < 0.01; cutoff value, 5.1; sensitivity, 84.2%; specificity, 43.4%). Conclusion: PGI levels of ≤37 ng/mL and PGI/II ratios of ≤5.1 effectively identified unintendedly eradicated cases in Group A.

Original languageEnglish
Pages (from-to)229-236
Number of pages8
JournalDigestion
DOIs
Publication statusAccepted/In press - 2017 Mar 30

Fingerprint

Pepsinogen A
Helicobacter Infections
Helicobacter pylori
ROC Curve
Stomach Neoplasms
Atrophy
Antibodies
Serum

Keywords

  • <italic>Helicobacter pylori</italic>
  • Gastric cancer screening
  • Pepsinogen
  • Risk stratification
  • Serum antibody

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels. / Kishikawa, Hiroshi; Hukuhara, Kayoko; Ito, Asako; Arahata, Kyoko; Takarabe, Sakiko; Kaida, Shogo; Miyauchi, Jun; Miura, Soichiro; Kanai, Takanori; Nishida, Jiro.

In: Digestion, 30.03.2017, p. 229-236.

Research output: Contribution to journalArticle

Kishikawa, Hiroshi ; Hukuhara, Kayoko ; Ito, Asako ; Arahata, Kyoko ; Takarabe, Sakiko ; Kaida, Shogo ; Miyauchi, Jun ; Miura, Soichiro ; Kanai, Takanori ; Nishida, Jiro. / Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels. In: Digestion. 2017 ; pp. 229-236.
@article{1db2d8d3f9584f66bfd00ee62c293efe,
title = "Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels",
abstract = "Backgrounds/Aims: In the ABC method, which is a method for risk stratification of gastric cancer using serum anti-Helicobacter pylori antibody and pepsinogen (PG) test, subjects with normal PG and seronegative for H. pylori are named as “Group A” and are regarded as having a low risk of gastric cancer. These “Group A” subjects include unintentionally eradicated cases at relatively high risk, and this study aimed to identify these subjects. Methods: Of the 109 subjects, 76 were classified as uninfected Group A subjects with negative histologic H. pylori infection and no histologic and endoscopic atrophy, and 33 subjects were classified serologically as Group A after successful eradication, which are serologically equal to the unintendedly eradicated cases in Group A. The usefulness of measuring PG levels to detect post-eradication cases was validated by using a receiver operating characteristic (ROC) curve analysis. Results: The area under the ROC curve for PGI level was 0.736 ± 0.06 (p < 0.01; cutoff value, 37.0 ng/mL; sensitivity, 77.6{\%}; specificity, 72.7{\%}), and that for the PGI/II ratio was 0.660 ± 0.06 (p < 0.01; cutoff value, 5.1; sensitivity, 84.2{\%}; specificity, 43.4{\%}). Conclusion: PGI levels of ≤37 ng/mL and PGI/II ratios of ≤5.1 effectively identified unintendedly eradicated cases in Group A.",
keywords = "<italic>Helicobacter pylori</italic>, Gastric cancer screening, Pepsinogen, Risk stratification, Serum antibody",
author = "Hiroshi Kishikawa and Kayoko Hukuhara and Asako Ito and Kyoko Arahata and Sakiko Takarabe and Shogo Kaida and Jun Miyauchi and Soichiro Miura and Takanori Kanai and Jiro Nishida",
year = "2017",
month = "3",
day = "30",
doi = "10.1159/000469705",
language = "English",
pages = "229--236",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels

AU - Kishikawa, Hiroshi

AU - Hukuhara, Kayoko

AU - Ito, Asako

AU - Arahata, Kyoko

AU - Takarabe, Sakiko

AU - Kaida, Shogo

AU - Miyauchi, Jun

AU - Miura, Soichiro

AU - Kanai, Takanori

AU - Nishida, Jiro

PY - 2017/3/30

Y1 - 2017/3/30

N2 - Backgrounds/Aims: In the ABC method, which is a method for risk stratification of gastric cancer using serum anti-Helicobacter pylori antibody and pepsinogen (PG) test, subjects with normal PG and seronegative for H. pylori are named as “Group A” and are regarded as having a low risk of gastric cancer. These “Group A” subjects include unintentionally eradicated cases at relatively high risk, and this study aimed to identify these subjects. Methods: Of the 109 subjects, 76 were classified as uninfected Group A subjects with negative histologic H. pylori infection and no histologic and endoscopic atrophy, and 33 subjects were classified serologically as Group A after successful eradication, which are serologically equal to the unintendedly eradicated cases in Group A. The usefulness of measuring PG levels to detect post-eradication cases was validated by using a receiver operating characteristic (ROC) curve analysis. Results: The area under the ROC curve for PGI level was 0.736 ± 0.06 (p < 0.01; cutoff value, 37.0 ng/mL; sensitivity, 77.6%; specificity, 72.7%), and that for the PGI/II ratio was 0.660 ± 0.06 (p < 0.01; cutoff value, 5.1; sensitivity, 84.2%; specificity, 43.4%). Conclusion: PGI levels of ≤37 ng/mL and PGI/II ratios of ≤5.1 effectively identified unintendedly eradicated cases in Group A.

AB - Backgrounds/Aims: In the ABC method, which is a method for risk stratification of gastric cancer using serum anti-Helicobacter pylori antibody and pepsinogen (PG) test, subjects with normal PG and seronegative for H. pylori are named as “Group A” and are regarded as having a low risk of gastric cancer. These “Group A” subjects include unintentionally eradicated cases at relatively high risk, and this study aimed to identify these subjects. Methods: Of the 109 subjects, 76 were classified as uninfected Group A subjects with negative histologic H. pylori infection and no histologic and endoscopic atrophy, and 33 subjects were classified serologically as Group A after successful eradication, which are serologically equal to the unintendedly eradicated cases in Group A. The usefulness of measuring PG levels to detect post-eradication cases was validated by using a receiver operating characteristic (ROC) curve analysis. Results: The area under the ROC curve for PGI level was 0.736 ± 0.06 (p < 0.01; cutoff value, 37.0 ng/mL; sensitivity, 77.6%; specificity, 72.7%), and that for the PGI/II ratio was 0.660 ± 0.06 (p < 0.01; cutoff value, 5.1; sensitivity, 84.2%; specificity, 43.4%). Conclusion: PGI levels of ≤37 ng/mL and PGI/II ratios of ≤5.1 effectively identified unintendedly eradicated cases in Group A.

KW - <italic>Helicobacter pylori</italic>

KW - Gastric cancer screening

KW - Pepsinogen

KW - Risk stratification

KW - Serum antibody

UR - http://www.scopus.com/inward/record.url?scp=85016556188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016556188&partnerID=8YFLogxK

U2 - 10.1159/000469705

DO - 10.1159/000469705

M3 - Article

C2 - 28355604

AN - SCOPUS:85016556188

SP - 229

EP - 236

JO - Digestion

JF - Digestion

SN - 0012-2823

ER -